Abstract:Background/Introduction Essential thrombocythemia (ET) is recognized for its hallmark elevated platelet count and a consequent increased risk of thromboembolic events including coronary events. Despite its clinical significance, the pathophysiological mechanisms predisposing ET patients to thrombosis remain largely undefined. Purpose The aim of this pioneering study was to shed light on the increased thrombotic risk in ET by conducting a detailed phenotypical characterization of platelet expression using single-cell mass cytometry, comparing ET patients to age- and sex-matched healthy controls. Methods Platelet samples from six patients diagnosed with ET and six healthy individuals were analyzed. This analysis utilized an extensive panel of 18 transmembrane regulators pivotal for platelet function and activation. Measurements were taken both at baseline and after ex-vivo stimulation with thrombin receptor-activating peptide (TRAP). Advanced clustering analysis via the FlowSOM algorithm helped identify specific subclusters of platelets with a prothrombotic expression profile. Results Our investigation revealed a significant overexpression of the activation marker CD62P (P-Selectin, p=0.049) and of the collagen receptor GPVI (p=0.044) in non-stimulated ET platelets (Figure 1A-C). Conversely, a notable decrease in expression was observed for the fibrinogen receptor GPIIb/IIIa units CD41 (p=0.036) and CD61 (p=0.044), as well as for the von Willebrand factor receptor CD42b (p=0.044). The FlowSOM analysis distinguished two prothrombotic subclusters of ET platelets, particularly highlighting one cluster, which was significantly overrepresented in ET (22.13% of total ET platelets versus 2.94% in controls, p=0.035, Figure 1D-E). Conclusion This study presents compelling evidence of a distinct prothrombotic phenotype in ET, marked by significant alterations in platelet expression profiles. The overexpression of CD62P and GPVI, alongside the underexpression of CD41, CD61, and CD42b, underscores the complex pathophysiological landscape of ET. Importantly, we identified a specific subcluster, particularly overrepresented in ET, with a specific prothrombic signature. Our findings, while only hypothesis generating, propose GPVI as a potential therapeutic target to mitigate thrombosis in ET patients, paving the way for targeted interventions in this high-risk population.

[The Study of Relationship Between Platelet Function and Thrombus in Patients with Essential Thrombocythaemia].

[Effects of Sodium Ozagrel in Primary Thrombocytosis Combined with Thrombosis].

Efficacy and Safety of Anagrelide in Treatment of Essential Thrombocythemia: Multicenter, Randomized Controlled Clinical Trial

Safety of Early Antiplatelet Therapy for Non-Cardioembolic Mild Stroke Patients with Thrombocytopenia.

Phagocytosis by endothelial cells inhibits procoagulant activity of platelets of essential thrombocythemia in vitro

Relations of Platelet Phospholipid Fatty Acids to Thrombotic Risk Factors in Middle-Aged and Geriatric Patients with Hyperlipidemia

A Study about the Relationship Between Thrombotic Events and Peripheral Neutrophil-to-Lymphocyte Ratio in Patients with Newly Diagnosed Essential Thrombocythemia

[The Incidence and Risk Factors for Thrombosis in Primary Immune Thrombocytopenia].

Single-cell mass cytometry analysis unveils prothrombotic expression and heterogeneity in essential thrombocythemia

The significance of differential mRNA expression of platelet function-associated genes in patients with venous thromboembolism

Increased reactive oxygen species lead to overactivation of platelets in essential thrombocythemia

Abstract 15499: the Increase of Proplatelets and Tpo in Circulation May Be a New Pathological Mechanism of Thrombosis

Percutaneous coronary intervention in patients with essential thrombocythemia: case reports and literature review.

Clinical analysis of essential thrombocythemia and pregnancy: treatment and outcomes

Relationship between thrombocytosis and all-cause in-hospital mortality in patients with chronic obstructive pulmonary disease and low-risk pulmonary embolism

Relationship Between rs768963 Gene Polymorphism of Thromboxane A2 Receptor and Platelet Aggregation

Influences of tirofiban hydrochloride on platelet aggregation rate,sCD40L level and prognosis in patients with non-ST-elevation acute coronary syndrome

Why Thromboembolism Occurs in Some Patients with Thrombocytopenia and Treatment Strategies

Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia

Dynamic Analysis for Level of Plasma TXB_2,6-keto-PGF_(1α) and TXB_2/6-keto-PGF_(1α) of Patients with Acute Cerebral Infarction and Its Clinic Significance

Reduced platelet activation in triple-negative essential thrombocythemia compared with JAK2V617F-mutated essential thrombocythemia